|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM354131532 |
| 003 |
DE-627 |
| 005 |
20231226061548.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109288
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1180.xml
|
| 035 |
|
|
|a (DE-627)NLM354131532
|
| 035 |
|
|
|a (NLM)36907538
|
| 035 |
|
|
|a (PII)S1521-6616(23)00067-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ding, Ying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Association between glomerular mTORC1 activation and crescents formation in lupus nephritis patients
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.04.2023
|
| 500 |
|
|
|a Date Revised 11.04.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a OBJECTIVE: This study aims to explore the association between glomerular mammalian target of rapamycin complex 1 (mTORC1) pathway activation and crescents' degree in lupus nephritis (LN) patients
|
| 520 |
|
|
|a METHODS: A total of 159 biopsy-proven LN patients were enrolled in this retrospective study. The clinical and pathological data of them were collected at the time of renal biopsy. mTORC1 pathway activation was measured by immunohistochemistry, expressed by the mean optical density (MOD) of p-RPS6 (ser235/236), and multiplexed immunofluorescence. The association of mTORC1 pathway activation with clinico-pathological features especially renal crescentic lesions, and the composite outcomes in LN patients was further analyzed
|
| 520 |
|
|
|a RESULTS: mTORC1 pathway activation could be detected in the crescentic lesions and was positively correlated with the percentage of crescents (r = 0.479, P < 0.001) in LN patients. Subgroup analysis showed mTORC1 pathway was more activated in patients with cellular or fibrocellular crescentic lesions (P < 0.001), but not fibrous crescentic lesions (P = 0.270). The optimal cutoff value of the MOD of p-RPS6 (ser235/236) was 0.0111299 for predicting the presence of cellular-fibrocellular crescents in >7.39% of the glomeruli by the receiver operating characteristic curve. Cox regression survival analysis showed that mTORC1 pathway activation was an independent risk factor for the worse outcome (defined by composite endpoints of death, end-stage renal disease and a decrease of >30% in eGFR from baseline)
|
| 520 |
|
|
|a CONCLUSION: Activation of mTORC1 pathway was closely associated with the cellular-fibrocellular crescentic lesions and could be a prognostic marker in LN patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Crescent
|
| 650 |
|
4 |
|a Lupus nephritis
|
| 650 |
|
4 |
|a mTORC1
|
| 700 |
1 |
|
|a Luan, Zhong-Qiu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mao, Zhao-Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qu, Zhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Feng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 249(2023) vom: 01. Apr., Seite 109288
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:249
|g year:2023
|g day:01
|g month:04
|g pages:109288
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109288
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 249
|j 2023
|b 01
|c 04
|h 109288
|